US court upholds patents on Pfizer's cancer drug

Credit: Reuters/Andrew Kelly

The Pfizer logo is seen at their world headquarters in New York April 28, 2014.

Pfizer filed the lawsuit in June 2010 after Mylan attempted to market a generic version of Sutent, patented until 2021.

Sutent, which is approved for use in advanced kidney cancer, gastrointestinal and pancreatic tumors, raked in sales of about $578 million in the first half of this year.

The case is Pfizer Inc v. Mylan Pharmaceuticals Inc, U.S. District Court, District of Delaware, No. 10-cv-00528-GMS.

(Reporting by Natalie Grover in Bangalore; Editing by Don Sebastian)